Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Anaesth Intensive Care ; 39(6): 1030-7, 2011 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-22165354

RESUMO

A prospective cohort study was performed to determine the optimal dose of vancomycin to maintain a serum trough concentration of at least 15 to 20 mg/l and to assess the efficacy of this target vancomycin concentration in the treatment of methicillin-resistant Staphylococcus aureus pneumonia. Vancomycin pharmacokinetic parameters were estimated using a CAPSIL software program from serum concentrations of 141 patients with pneumonia treated with vancomycin, regardless of methicillin-resistant Staphylococcus aureus status, at a 28-bed medical intensive care unit. Vancomycin trough concentrations and other pharmacokinetic parameters were compared between five groups of patients differing in their renal function: (1) creatinine clearance > or =60 ml/minute, (2) creatinine clearance 30 to 60 ml/minute, (3) creatinine clearance <30 ml/minute, (4) on intermittent haemodialysis, and (5) on continuous renal replacement therapy. More than 70% of patients failed to reach the recommended therapeutic serum trough concentrations: a higher dose of vancomycin is necessary to maintain serum trough concentration at 15 to 20 mg/l, particularly in critically ill patients with creatinine clearance above 60 ml/minute and in those on intermittent haemodialysis. Among patients with methicillin-resistant Staphylococcus aureus pneumonia, no significant differences were observed in the treatment success rate, length of intensive care unit stay, and intensive care unit mortality rate between patients with vancomycin trough concentrations of >20 mg/l, 15 to 20 mg/l and <15 mg/l.


Assuntos
Antibacterianos/administração & dosagem , Antibacterianos/uso terapêutico , Estado Terminal , Staphylococcus aureus Resistente à Meticilina , Pneumonia Estafilocócica/tratamento farmacológico , Vancomicina/administração & dosagem , Vancomicina/uso terapêutico , APACHE , Adolescente , Adulto , Idoso , Antibacterianos/farmacocinética , Área Sob a Curva , Estudos de Coortes , Cuidados Críticos , Relação Dose-Resposta a Droga , Feminino , Meia-Vida , Humanos , Rim/fisiopatologia , Testes de Função Renal , Masculino , Pessoa de Meia-Idade , Pneumonia Estafilocócica/microbiologia , Pneumonia Estafilocócica/mortalidade , Estudos Prospectivos , Falha de Tratamento , Resultado do Tratamento , Vancomicina/farmacocinética , Adulto Jovem
3.
J Obstet Gynaecol Res ; 25(5): 321-6, 1999 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-10533326

RESUMO

The primary carcinoma of the fallopian tube is the rarest of all gynecologic malignancies and histologically most of them are adenocarcinomas. Primary transitional cell carcinomas are extremely rare in the fallopian tube. A 63-year-old postmenopausal woman presenting with lower abdominal pain was found to have a left adnexal mass. Exploratory laparotomy revealed a mass arising from the fallopian tube with the histologic features of transitional cell carcinoma. Light and electron microscopic studies supported the notion of transitional cell carcinoma. The tumor was extended to the muscle layer and confined to the left fallopian tube without metastasis. The patient received 3 courses of systemic cisplatin-based chemotherapy and has been well with no evidence of recurrence until August, 1998.


Assuntos
Carcinoma de Células de Transição/diagnóstico , Neoplasias das Tubas Uterinas/diagnóstico , Dor Abdominal , Carcinoma de Células de Transição/patologia , Carcinoma de Células de Transição/terapia , Cisplatino/uso terapêutico , Neoplasias das Tubas Uterinas/patologia , Neoplasias das Tubas Uterinas/terapia , Tubas Uterinas/cirurgia , Feminino , Humanos , Microscopia Eletrônica , Pessoa de Meia-Idade , Ovariectomia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...